Interferons News and Research

RSS

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Study could help in developing therapeutic strategies for Chikungunya virus infection

A study published online on February 1 in the Journal of Experimental Medicine (www.jem.org) shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.

2 Feb 2010

Investigators identify new disease mechanism and therapeutic approach for lupus kidney disease

Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The

27 Jan 2010

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

5 Jan 2010

Scientists explain how smallpox viruses disrupt immune systems

A team of researchers working in a high containment laboratory at the Centers for Disease Control and Prevention in Atlanta, GA, have solved a fundamental mystery about smallpox that has puzzled scientists long after the natural disease was eradicated by vaccination.: they know how it kills us.

23 Dec 2009

Human protein may help prevent H1N1 infection

Howard Hughes Medical Institute researchers have identified a naturally occurring human protein that helps prevent infection by H1N1 influenza and other viruses, including West Nile and dengue virus.

18 Dec 2009

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

In findings that may lead to better ways to prevent and treat influenza and other viral infections, researchers report the discovery of a family of naturally occurring antiviral agents in human cells.

18 Dec 2009

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

Comparative study on African monkeys may provide novel targets for AIDS therapy

Two studies published this month in the Journal of Clinical Investigation provide a significant advance in understanding how some species of monkeys such as sooty mangabeys and African green monkeys avoid AIDS when infected with SIV, the simian equivalent of HIV.

5 Dec 2009

Scientists discover mechanism by which E6 oncoprotein of high-risk HPV16 promotes carcinogenesis

In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to degenerate. It is known today that the main culprits are viral proteins E6 and E7. Both proteins switch off different cellular control functions, thus promoting cell growth.

4 Dec 2009

Russian hepatitis C virus drug market to reach $327M by 2013: Decision Resources

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the hepatitis C virus drug market in Russia will grow nine percent annually over the 2008 - 2013 study period, reaching $327 million by 2013.

1 Dec 2009

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.

2 Nov 2009

Phase 2 clinical study of PEG-Interferon lambda commenced

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the “EMERGE” study).

27 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Researchers study functional similarity between zebrafish and humans to fight infections

Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms. Zebrafish are becoming an important model for human disease, since they are easily handled, maintained and manipulated and many fundamental processes between zebrafish and humans are conserved.

24 Sep 2009